Condition:   Acute Gout
Interventions:   Drug: ACZ885;   Drug: Triamcinolone acetonide
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: NN1250;   Drug: insulin glargine
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Medication Reconciliation;   Emergency Department
Intervention:   Other: Medication reconciliation completed by a RN, CPhT, or RPh
Sponsors:   Wesley Medical Center;   Cardinal Health Foundation
Recruiting - verified January 2010

Condition:   Sexual Dysfunctions, Psychological
Interventions:   Drug: Flibanserin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified February 2010

Conditions:   Pulmonary Disease, Chronic Obstructive;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: FF/GW642444 Inhalation Powder;   Drug: Placebo;   Drug: FF Inhalation Powder;   Drug: GW642444 Inhalation Powder
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Influenza
Interventions:   Drug: Oseltamivir;   Drug: Oseltamivir
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Hypertriglyceridemia
Interventions:   Drug: AMR101 (ethyl icosapentate);   Drug: AMR101 (ethyl icosapentate);   Drug: Placebo
Sponsor:   Amarin Pharma Inc.
Recruiting - verified February 2010

Conditions:   Type 2 Diabetes Mellitus;   Cardiovascular Disease;   Hypertension;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: Seneca Valley virus-001;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Healthy
Intervention:   Procedure: Blood draw
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: tociliumab;   Drug: methotrexate
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Melanoma
Interventions:   Drug: Tasisulam;   Drug: Paclitaxel
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Conditions:   Cognitive Dysfunction;   Schizophrenia
Interventions:   Drug: TC-5619;   Drug: Placebo
Sponsor:   Targacept Inc.
Recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: cetuximab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions:   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Schizophrenia
Interventions:   Drug: PF-03463275;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Influenza Infection
Interventions:   Biological: GSK2340273A;   Biological: GSK2340274A
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type II
Interventions:   Drug: Placebo;   Drug: Dutogliptin
Sponsors:   Forest Laboratories;   Phenomix
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Hot Flashes;   Menopausal Symptoms;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: flaxseed;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Dyslipidemia
Interventions:   Drug: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: Extended-release niacin (ERN);   Drug: Comparator: Placebo to ERN/LRPT
Sponsor:   Merck
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type II
Interventions:   Drug: Dutogliptin;   Drug: Placebo
Sponsors:   Forest Laboratories;   Phenomix
Recruiting - verified February 2010

Conditions:   Cervical Cancer;   Vulvar Cancer;   Vaginal Cancer;   Genital Lesions;   PAP Test Abnormalities;   HPV Infections
Intervention:   Biological: V503
Sponsor:   Merck
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: capecitabine;   Drug: docetaxel;   Drug: fluorouracil;   Drug: oxaliplatin
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Carcinoma of Unknown Primary
Interventions:   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Intervention:   Drug: Dimebon
Sponsors:   Pfizer;   Medivation, Inc.
Recruiting - verified March 2010

Condition:   Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions:   Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
Sponsors:   Regeneron Pharmaceuticals;   Bayer
Recruiting - verified February 2010

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor:   Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010

Condition:   HIV
Interventions:   Drug: atazanavir/raltegravir;   Drug: atazanavir/raltegravir;   Drug: atazanavir/tenofovir/emtricitabine
Sponsor:   Community Research Initiative of New England
Recruiting - verified February 2010

Condition:   Overactive Bladder
Interventions:   Drug: Fesoterodine;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Attention Deficit Disorder With Hyperactivity
Interventions:   Drug: Placebo;   Drug: OROS MPH
Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010

Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: Teplizumab (MGA031);   Drug: Placebo
Sponsors:   MacroGenics;   Eli Lilly and Company
Recruiting - verified February 2010

Conditions:   Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Peritoneal Cavity Cancer;   Small Intestine Cancer
Interventions:   Drug: palonosetron hydrochloride;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Other: biologic sample preservation procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Idiopathic Pulmonary Fibrosis
Interventions:   Drug: ACT-064992 (macitentan);   Drug: Placebo
Sponsor:   Actelion
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Drug: capecitabine;   Drug: sunitinib malate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: tocilizumab [RoActemra];   Drug: Nonbiologic DMARDs of investigator's choice
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: systemic chemotherapy;   Procedure: axillary lymph node dissection;   Procedure: neoadjuvant therapy;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: ultrasound imaging
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: dexamethasone;   Drug: gabapentin;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Liver Cancer
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment
Sponsors:   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Chemotherapeutic Agent Toxicity;   Neurotoxicity;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: paclitaxel;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: assessment of therapy complications
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: Everolimus, Exemestane;   Drug: Placebo, Exemestane
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Crohn´s Disease
Interventions:   Drug: Pentasa;   Drug: Placebo
Sponsor:   Ferring Pharmaceuticals
Recruiting - verified February 2010

Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Alogliptin and metformin;   Drug: Alogliptin and metformin;   Drug: Glipizide and metformin
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Placebo;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: CP 690,550;   Drug: CP-690,550;   Other: Placebo;   Other: Placebo;   Biological: Biologic TNFi
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Colorectal Cancer (CRC)
Interventions:   Drug: Irinotecan;   Drug: 5-Fluorouracil (bolus);   Drug: 5-Fluorouracil (infusional);   Drug: Leucovorin calcium;   Drug: CT-322;   Drug: Bevacizumab;   Drug: Bevacizumab Placebo (saline solution)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Non-small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: CT-322;   Drug: Bevacizumab;   Drug: Bevacizumab placebo (ie saline solution)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Major Depressive Disorder
Interventions:   Drug: Placebo;   Drug: fluoxetine;   Drug: duloxetine;   Drug: duloxetine
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: idarubicin;   Drug: pravastatin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Gastroparesis;   Diabetic Gastroparesis;   Diabetes;   Diabetes Mellitus;   Delayed Gastric Emptying
Interventions:   Drug: metoclopramide;   Drug: Placebo
Sponsor:   Evoke Pharma
Recruiting - verified March 2010

Conditions:   Metastatic;   Colorectal Cancer
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin);   Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors:   Bayer;   Onyx Pharmaceuticals
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Biological: aflibercept;   Drug: topotecan hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Arthritis;   Osteoarthritis
Interventions:   Biological: tanezumab 10 mg;   Biological: tanezumab 5 mg;   Drug: naproxen;   Other: placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: deforolimus;   Drug: Comparator: Blinded Ridaforolimus;   Drug: Comparator: Blinded Placebo
Sponsors:   Merck;   Ariad Pharmaceuticals
Recruiting - verified March 2010

Condition:   Metastatic Colorectal Cancer
Interventions:   Biological: AMG 479;   Other: Placebo;   Other: FOLFIRI;   Biological: AMG 655
Sponsor:   Amgen
Recruiting - verified February 2010

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Myocardial Ischemia;   Unstable Angina
Intervention:   Drug: Rivaroxaban; Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Bayer
Recruiting - verified February 2010

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: infliximab;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: sham
Sponsor:   Genentech
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: pemetrexed disodium;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: active surveillance
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Secondary Hyperparathyroidism;   Chronic Kidney Disease
Interventions:   Drug: Cinacalcet;   Drug: Vitamin D
Sponsor:   Amgen
Recruiting - verified February 2010

Condition:   Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention:   Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cladribine;   Drug: temsirolimus;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Other: mass spectrometry
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Colon Cancer;   Colorectal Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Pulmonary Fibrosis
Intervention:   Drug: CNTO 888
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Other: clinical observation;   Radiation: radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Fatigue;   Neuropathy;   Neurotoxicity
Interventions:   Dietary Supplement: acetyl-L-carnitine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Biological: tositumomab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: iodine I 131 tositumomab
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:   Drug: ambrisentan or sugar pill
Sponsor:   Gilead Sciences
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Biological: Bevacizumab
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: rhGAD65;   Drug: rhGAD65;   Drug: Placebo
Sponsor:   Diamyd Therapeutics AB
Recruiting - verified March 2010

Condition:   Prostatic Neoplasms
Interventions:   Drug: placebo + docetaxel/prednisone;   Drug: dasatinib + docetaxel/prednisone
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: ASA404 in combination with docetaxel;   Drug: Placebo in combination with docetaxel
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Diabetes Mellitus
Interventions:   Drug: Exubera;   Other: Randomized diabetes therapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: American ginseng;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: carmustine;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: melphalan;   Drug: thalidomide;   Procedure: autologous-autologous tandem hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Melanoma (Skin)
Intervention:   Drug: dasatinib
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: sunitinib malate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Attention Deficit Hyperactivity Disorder
Interventions:   Drug: atomoxetine hydrochloride;   Drug: placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Drug: capecitabine;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic surgical procedure;   Radiation: radiation therapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Thoracic Radiation Therapy (TRT);   Radiation: Thoracic Radiation Therapy (TRT)
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Drug: azacitidine;   Drug: gemtuzumab ozogamicin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: midostaurin;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: panitumumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: lenalidomide
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: lenalidomide;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Drug: SD-6010;   Drug: SD-6010;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Metastatic Breast Cancer
Interventions:   Drug: docetaxel;   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab
Sponsors:   Genentech;   Roche Pharma AG
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: panitumumab;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Tibial Fractures
Interventions:   Drug: CP-533, 536;   Drug: Placebo;   Procedure: Standard of Care;   Drug: CP-533,536;   Drug: CP-533,536;   Drug: CP-533,536
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction
Interventions:   Drug: SCH 530348;   Drug: Placebo
Sponsors:   Schering-Plough;   Duke University
Recruiting - verified February 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Epilepsy
Interventions:   Drug: lacosamide;   Drug: lacosamide
Sponsor:   UCB, Inc.
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: paclitaxel
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: bortezomib, thalidomide, and dexamethasone (VTD);   Drug: bortezomib and dexamethasone (VD);   Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin;   Other: clinical observation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Neurotoxicity;   Pain;   Peripheral Neuropathy;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Invasive Breast Cancer
Interventions:   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: trastuzumab;   Drug: lapatinib
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   GlaxoSmithKline
Recruiting - verified February 2010

Conditions:   Neurotoxicity;   Pain;   Peripheral Neuropathy;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: ketamine/amitriptyline NP-H cream;   Other: placebo
Sponsors:   University of Rochester;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Lung Cancer
Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions:   Drug: cisplatin + Docetaxel;   Drug: Panitumumab
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Small Intestine Cancer
Interventions:   Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions:   Drug: motesanib diphosphate;   Drug: octreotide acetate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Procedure: computed tomography
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:   Drug: maraviroc
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Metastatic Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFIRI - Panitumumab;   Drug: FOLFIRI - Bevacizumab
Sponsor:   Amgen
Recruiting - verified February 2010

Condition:   Arthritis, Rheumatoid
Intervention:   Other: CP-690,550
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: conventional surgery
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: lapatinib ditosylate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Drug: chemotherapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified June 2009

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate;   Drug: temsirolimus
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Lymphedema;   Perioperative/Postoperative Complications
Interventions:   Behavioral: exercise intervention;   Other: educational intervention;   Procedure: assessment of therapy complications;   Procedure: complementary or alternative medicine procedure;   Procedure: management of therapy complications;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Osteoarthritis
Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Pain;   Prostate Cancer
Interventions:   Dietary Supplement: calcium carbonate;   Dietary Supplement: calcium citrate;   Dietary Supplement: calcium glucarate;   Dietary Supplement: vitamin D;   Drug: calcium gluconate;   Drug: zoledronic acid;   Radiation: samarium Sm 153 lexidronam pentasodium;   Radiation: strontium chloride Sr 89
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Intervention:   Biological: aflibercept
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Epilepsies, Partial
Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Leukemia
Intervention:   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: sorafenib tosylate;   Drug: temsirolimus
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified March 2010

Condition:   Anal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: entinostat
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Biological: trastuzumab;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: bortezomib;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Biological: alemtuzumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: pentostatin
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Menopausal Symptoms;   Sexual Dysfunction and Infertility
Interventions:   Drug: cyclophosphamide;   Drug: goserelin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   International Breast Cancer Study Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: capecitabine;   Drug: fluorouracil;   Drug: oxaliplatin;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: imatinib mesylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009

Condition:   Melanoma (Skin)
Interventions:   Biological: recombinant interferon alfa;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Children's Oncology Group
Recruiting - verified March 2010